Gene Dubowchik

Gene has 30 years of experience in medicinal chemistry, specifically in Neuroscience and Oncology. He joined Biohaven from Bristol-Myers Squibb where he led efforts in antibody-drug conjugates for cancer and contributed to diverse neuroscience programs in migraine (CGRP antagonists), depression (CRF antagonists, ion channel blockers), FK-506 binding proteins (FKBPs, immunophilins), Alzheimer's Disease (GSK-3 inhibitors) and sleep (melatonin agonists and antagonists). He oversaw chemist teams leading to the discovery of two CGRP receptor antagonist clinical candidates, BHV-3000 (formerly BMS-927711) for oral delivery, and BHV-3500 (formerly BMS-742413) for intranasal delivery. He also developed the dipeptide-based linkage system used in the antibody drug conjugate (ADC) Adcetris®, approved by the FDA in 2011, and numerous other ADCs now in clinical trials and pre-clinical development. Gene received his Ph.D. in organic chemistry from Princeton University and did postdoctoral work at the University of British Columbia. He received his bachelor’s degree from Franklin and Marshall College, majoring in chemistry and history.